Psoriasis treatment patterns: a retrospective claims study

Abstract

Objective: The objective was to characterize psoriasis treatment patterns, including estimating persistence and describing subsequent events (i.e. switching and restarting) for all systemic therapies.

Methods: This retrospective cohort study utilized Truven MarketScan databases from 1 January 2014 to 31 December 2016 to investigate persistence, switching and restarting in new users of systemic psoriasis medications. Descriptive statistics, time-to-event analyses and a Cox proportional hazards regression were conducted.

Results: A total of 5205 patients met inclusion criteria. Regardless of treatment type, >50% lost persistence by 12 months. Patients newly initiating acitretin or non-TNF biologic experienced the highest loss of persistence (85.2%, 73.8%, respectively). Patients initiating a TNF-α inhibitor or apremilast experienced the lowest loss (51.8%, 56.4% respectively). Treatment type had a statistically significant effect on persistence loss (adjusted hazard ratio: 0.86, 95% CI: 0.81, 0.91). Restarting was the most commonly observed event for patients on an oral or biologic (60.2%, 79.9%, respectively). The most common switch from an oral was to a TNF-α inhibitor, while apremilast often followed biologics.

Conclusion: Most patients lost persistence on initial treatment by 12 months, and the majority restarted treatment. This may indicate poor compliance or the cyclical nature of psoriasis. More patients switched from an oral to biologic than vice versa, likely due to formulary design and preference for orals. Studies are needed to investigate underlying reasons and patient characteristics that differentiate treatment utilization.

Keywords:

• Observational research
• treatment patterns
• psoriasis
• claims data

Transparency

Author contributions

All authors designed the study. D.W. prepared the analytic data set. S.H. performed the data analysis and drafted the manuscript. All authors contributed to revising the manuscript.

Declaration of financial/other relationships

V.P., S.B. and D.W. have disclosed that they are employees of Allergan Inc. S.H. has disclosed that she is funded by the University of Washington CHOICE Institute Fellowship sponsored by Allergan Inc. No potential conflict of interest was reported by the other authors. A reviewer on this manuscript has disclosed being an employee of Mount Sinai and receiving research funds from AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, Medimmune/Astra Zeneca, Novartis, Pfizer, Sciderm, Valeant and ViDac. The same reviewer has also disclosed being a consultant for Allergan, Aqua, Boehringer Ingelheim, LEO Pharma, Menlo, Mitsubishi, Promius and Theravance. CMRO peer reviewers on this manuscript have no other relevant financial or other relationships to disclose.

Additional information

Funding

This study was supported by a training grant to the University of Washington funded by Allergan, Inc.